Shanghai Junshi Biosciences Co (SHSE:688180) Total Current Assets : ¥4,821 Mil (As of Jun. 2024)

View and export this data going back to 2020. Start your Free Trial

What is Shanghai Junshi Biosciences Co Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. Shanghai Junshi Biosciences Co's total current assets for the quarter that ended in Jun. 2024 was ¥4,821 Mil.

Shanghai Junshi Biosciences Co Total Current Assets Historical Data

The historical data trend for Shanghai Junshi Biosciences Co's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Shanghai Junshi Biosciences Co Total Current Assets Chart

Shanghai Junshi Biosciences Co Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

1,911.12

4,698.72

5,831.74

7,204.91

5,549.83

Shanghai Junshi Biosciences Co Semi-Annual Data
	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Current Assets	Get a 7-Day Free Trial											4,626.23	7,204.91	6,411.93	5,549.83	4,820.90

Shanghai Junshi Biosciences Co Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

Shanghai Junshi Biosciences Co's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3778.142	+	479.723	+	538.053	+	753.909
	=	5,550

Shanghai Junshi Biosciences Co's Total Current Assets for the quarter that ended in Jun. 2024 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	3311.469	+	635.995	+	554.107	+	319.326
	=	4,821

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

Shanghai Junshi Biosciences Co (SHSE:688180) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

Shanghai Junshi Biosciences Co's Liquidation Value for the quarter that ended in Jun. 2024 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	3311.469	-	4384.456	+	0.75 * 449.904	+	0.5 * 554.107
=	-459

Shanghai Junshi Biosciences Co Total Current Assets Related Terms

Thank you for viewing the detailed overview of Shanghai Junshi Biosciences Co's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

Shanghai Junshi Biosciences Co Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Shanghai Junshi Biosciences Co Ltd (SHSE:688180) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

SHJBF:USA 01877:Hong Kong 8SJ:Germany

Address

Nos. 36 and 58, Hai Qu Road, Room 1003, Level 10, Building 2, Pilot Free Trade Zone, Shanghai, CHN

Website

https://www.junshipharma.com

Shanghai Junshi Biosciences Co Ltd is a China-based biotechnology companyy with all-round capabilities in innovative drug discovery and development, clinical research on a global scale, large-scale production capacity to commercialization on the full industry chain. Aiming to develop first-in-class or bestin-class drugs by way of original innovation and co-development. Companies operations are located in the PRC and the USA.

Executives

	Directors, senior managers
Chen Ying Ge	senior management
Xiong Jun	Director
Yin Kan	senior management
Xie Wan	senior management

Shanghai Junshi Biosciences Co Headlines

No Headlines